The Effect of Methylphenidate on Cognitive Abilities of Adults With Bipolar Disorder

N/AUnknownNCT02020200

Shalvata Mental Health Center40 enrolled

Overview

The purpose of the study is to explore the effect of MPH on working memory, attention and decision making in adults with BD in remission or in depressed state. The results will be compared to findings in healthy adults and adults with ADHD. The investigators hypothesize that MPH will incur improved performance in all measures.

Following a detailed explanation about the trial and after obtaining informed consent from candidates, subjects will be asked to arrive at the cognitive laboratory at Shalvata MHC twice. Visits will include performance of computerized cognitive and decision making tasks, as well as two creativity tasks after the consumption of MPH or placebo.

Study Type

INTERVENTIONAL

Purpose

DIAGNOSTIC

Masking

QUADRUPLE

Enrollment

Conditions

Interventions

MPHDRUG

MPH dosage will be determined according to participants' body weight: dosage: 10 mg in case weight\<40 kg; 30 mg in case weight\>90 kg; otherwise 20 mg.

PlaceboDRUG

Eligibility

Sex: ALLMin age: 21 YearsMax age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Hebrew Speakers * Age 21-50 * Diagnosis of BD I or II (296.7 and 296.89 classifications in the DSM-IV-TR), according to medical records. Diagnosis will be confirmed by a psychiatrist during screening process using the Structured Clinical Interview for DSM-IV-TR (SCID). Exclusion Criteria: * Diagnosis of a clinical disorder other than BD or ADD/ADHD which may impair performance on tasks used in the study. * BD patients diagnosed with an acute manic episode at screening, as established by YMRS\>8. It will also be required that 3 months have elapsed since the latest manic state, according to the patients' history. * Participants for whom there exists a contra-indication for consuming Ritalin. * Pregnancy or current breastfeeding; Female participants will be asked to report whether they are pregnant or currently nursing and if so, they will be excluded from the study. * Drug use in the previous 6 weeks according to participants' self report * Electroconvulsive therapy (ECT) in the previous 6 months

Locations (1)

Shalvata MHC

Hod HaSharon, Israel

Outcomes

Primary Outcomes

Cognitive function.

Cognitive function will be measured by scores on several computerized neuro-psychological and decision making tasks: digit-span task, spatial working memory task, raven's progressive matrices, test of variable attention and the Iowa gambling task.

Time frame: Within 4 hours of intervention.

Secondary Outcomes

Creativity abilities.

Creativity will be measured by scores on two tests: the alternative use task and two subsets of the Torrance tests for creative thinking.

Time frame: Within 4 hours of intervention.

Central Contacts

Yael Lewis, MD

CONTACT

+97297478644 yaelle4@clalit.org.il

Yechiel Levkovitz, MD, PhD

CONTACT

+97297478644

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.